Skip to main content
. 2023 Jun 19;14:3631. doi: 10.1038/s41467-023-39376-7

Fig. 4. GMTs and GMFRs of anti-hemagglutinin antibodies for vaccine-matched seasonal influenza strains in adults in Part 2.

Fig. 4

Hemagglutination inhibition GMTs with associated 95% CIs against seasonal influenza A strains (A/Wisconsin/588/2019[H1N1]pdm09 and A/Cambodia/e0826360/2020[H3N2]) or influenza B strains (B/Washington/02/2019 (B/Victoria lineage) and B/Phuket/3073/2013 (B/Yamagata lineage)) are shown at Day 1 (baseline) and Day 29 (28 days after vaccination) among participants a 18–49 years, b 50–64 years, and c ≥65 years of age in the per-protocol population for Part 2. Dots corresponding to participant-level titers; numbers of participants in the Afluria groups were 20 (18–49 years), 20 (50–64 years), and 12 (≥65 years); numbers of participants in the mRNA-1010 groups were 55 (25 µg), 53 (50 µg), and 58 (100 µg) for 18–49 years; 57 (25 µg), 54 (50 µg), and 54 (100 µg) for 50–64 years; and 31 (25 µg), 31, (50 µg), and 30 (100 µg) for ≥65 years. GMFRs at Day 29 from Day 1 are shown above each Day 29 bar plot. LLOQs were 10 for each influenza strain; ULOQs were 6400 (H1N1 and B/Yamagata), 1280 (H3N2), or 3200 (B/Victoria). HAI GMTs <LLOQ were replaced by 0.5× LLOQ and values >ULOQ were converted to ULOQ. CI confidence interval, HAI hemagglutination inhibition, GMFR geometric mean fold-rise, GMT geometric mean titer, LLOQ lower limit of quantification, mRNA messenger RNA, ULOQ upper limit of quantification.